IL2 and head and neck squamous cell carcinoma: Rapid advancement of HIV-specific ISTs into clinical trials will be supported by the excellent safety profile of IST constructs incorporating affinity-attenuated IL-2 (28, 29), which are under clinical evaluation for recurrent metastatic HPV-positive head and neck squamous cell carcinoma and WT1+ metastatic solid cancers (NCT03978689/NCT04852328 and NCT05360680).